Heart failure is a complex multifactorial disease resulting in a myriad of progressive changes at the molecular, cellular, and physiological level. To better understand the mechanisms associated with the development of congestive heart failure, a comprehensive examination of the aging lean male spontaneously hypertensive heart failure-prone rat (SHHF) was conducted. Myocardial function and structural integrity progressively diminished as evidenced by decreased ejection fraction and increased left ventricular volume measured using echocardiography. Functional and structural changes were accompanied by elevations in circulating inflammatory markers including tumor necrosis factor alpha (TNF-α), interleukin-6 (IL-6), and TNF receptors type 1 and 2 (TNFR1 and TNFR2). Increased systemic inflammatory marker levels were consistent with age-dependent changes in the expression pattern of genes that contribute to stress, inflammation, and the extracellular matrix in SHHF animals analyzed from age 4 to 18 months.
Introduction
Heart failure (HF) is defined as the inability of the heart to pump blood at a rate commensurate with the metabolic demands of the body or can only do so at elevated filling pressures (6, 23) . As such, congestive heart failure (CHF) can be attributed to multiple factors including: diastolic dysfunction, systolic dysfunction, inflammation, and changes in neurohormonal regulators, which affect blood pressure and fluid retention. The complexity of the disease has contributed undoubtedly to the continued growth of the diagnosed CHF population despite the extensive arsenal of available therapies. In fact, it is estimated that by 2007 there will be 10 million cases of HF in the United Stated alone (30) with six-year mortality rates for men and women at 84% and 77%, respectively (7) .
It is well established that initiation of CHF pathophysiology is a multifactorial process encompassing physiological, neurohormonal, biochemical, molecular, and cellular changes, the culmination of which is the activation of compensatory mechanisms that aim to maintain heart function but, when prolonged, evolve into maladaptive processes. For example, initial structural alterations during HF development maintain cardiac output, however, extensive left ventricular (LV) remodeling becomes deleterious and contributes to decompensation. In addition, levels of pro-inflammatory cytokines that initially facilitate tissue repair in CHF increase concomitantly with the severity of HF (11, 36) and have been correlated with left ventricular dysfunction, edema, cardiomyopathy, remodeling, and mortality (11, 14, 18, 29) . Collectively, these and other compensatory systems initially work to maintain cardiac function and output. However, prolonged activation of these systems results in tissue damage, organ failure and ultimately, death.
The Spontaneously Hypertensive Heart Failure-prone (SHHF) rat represents a congenital model of dilated cardiomyopathy with hypertension progressing to decompensated heart failure which exhibits several hallmark signs of the human disease state. For example, as SHHF animals age, many of the biochemical and physiological compensatory systems observed in human patients are also activated in this model. Documented biochemical compensatory mechanisms recapitulated in the SHHF model include renin angiotension aldosterone system (RAAS) activation, natriuretic peptide elevation and tumor necrosis factor alpha (TNF-α) elevation (2, 20) . Common pathophysiologic outcomes of end-stage human heart failure such as increased end diastolic volume and decreased ejection fraction have also been evidenced in the SHHF animals (1, 5, 34) .
Although the SHHF rat represents a commonly employed experimental model of HF, a comprehensive evaluation of the structural, functional, and molecular mediators of pathophysiology in this model has not been conducted. To further understand the underlying mechanisms of CHF progression, we temporally characterized the lean male SHHF rat model from 4 to 18 months of age. Our results couple progressive pathophysiological changes, profiled using echocardiography, with serum and tissue biochemical markers, and the expression patterns of key cytokines, stress and matrix molecules that contribute to CHF pathophysiology.
Methods
Animals. The present study was conducted in accordance with institutional guidelines for the humane treatment of animals using both homozygous (cp/cp) and heterozygous (+/cp) lean male SHHF rats obtained from Genetic Models Inc. (Indianapolis, IN). All animals were housed in a room lit 12 hours per day (6 a.m.-6 p.m.) at an ambient temperature of 22 ± 1°C. Animals were allowed one week to adjust after arrival and were allowed access to rodent diet and tap water ad libitum for the duration of the experiment. SHHF rats used in the study were categorized according to age and ranged from 4 to 18 months of age with an n ranging from 10 to 13 unless otherwise noted.
Systolic Blood Pressure. Systolic blood pressure was analyzed using the Visitech BP-2000 Blood Pressure Analysis System (Visitech Systems, Apex, NC). The BP-2000 computerized non-invasive tail cuff system was set to measure 6 cycles (1 cycle every 30 seconds) with an upper pulse rate limit of 15 Hz and minimum average pulse amplitude at 20% of full-scale. The BP-2000 system was calibrated before each data collection period using a manometer to accurately obtain systolic pressure. Animals were randomly brought into a dimly lit quiet room and blood pressure measurements were taken. Briefly, rats were lightly anesthetized with 0.5-1 % isoflurane (AErrane; Baxter Inc., Deerfield, IL) and placed on a warming table with tails inserted into cuffs. Six measures were taken for each animal and averaged for a mean systolic blood pressure reading.
Echocardiography. Echocardiograms were performed using the Agilent SONOS 5500 echocardiographic system equipped with a 15-MHz linear-array transducer (Agilent, Andover, MA). Images were obtained from rats lightly anesthetized with 1-2% isoflurane (AErrane; Baxter, Inc., Deerfield, IL) lying on their left side with transducer placed on the left hemithorax. Two-dimensional parasternal long and short-axis images of the left ventricle were obtained, and two-dimensional targeted M-mode tracings were recorded from the parasternal short-axis view at the level of the papillary muscles at a sweep speed of 150 mm/s. Doppler flow velocities were taken at the level of the mitral valve in the apical 4-chamber view with the Doppler probe placed at the edge of the mitral leaflets. All measurements were performed according to the recommendations of the American Society for Echocardiography leading-edge method from three consecutive cardiac cycles (31). Measurements and calculations used are as follows: percent LV fractional shortening (FS) was calculated as follows: FS = (LVIDd -LVIDs) / LVIDd × 100, where LVIDd and LVIDs are end-diastolic and end-systolic LV internal dimensions, respectively. Relative wall thickness (RWT) was calculated as (PWd + IVSd) / LVIDd, where PWd and IVSd are end-diastolic posterior wall and interventricular septal thickness, respectively. End diastolic (EDV) and systolic (ESV) volumes were calculated from LV systolic (LVAs) and diastolic (LVAd) areas via the method of discs (31). Ejection Fraction (EF) was calculated from systolic and diastolic volumes with the following formula: EF = (EDV-ESV) / EDV × 100. Other measurements taken include early filling velocity (E-velocity; E-vel), late filling velocity (A-velocity; A-vel), mitral valve deceleration time (Decel T), LV mass (area length method), heart rate (HR; m-mode R-R interval), stroke volume (SV; SV = EDV-ESV) and cardiac output (CO = SV * HR).
Tissue Processing, Staining, Imaging, and Analysis. Equatorial regions of the heart fixed in 10% neutral buffered formalin were routinely processed and paraffin-embedded. Ten-micron sections were stained with the collagen specific stain Picro-Sirius Red F3BA for determination of interstitial collagen volume fraction using a Videometric 150 Image Analysis System (Oncor Inc., Gaitherburg, MD) as previously described (8) . Five-micron sections were stained with hemotaoxylin & eosin and trichrome for histopathological analysis. Myocardial lesions of fibrosis, hypertrophy, degeneration, necrosis, and inflammatory cell infiltrates were classified and scored in 5 to 6 rats per group at 5, 9, and 16 months of age and in 9 rats at 18 months of age. Lesions were scored as 0 (absent), 1 (minimal), 2 (mild), 3 (moderate), or 4 (marked).
Immunohistochemistry. Five-micron sections were deparaffinized, rehydrated in ethanol, and processed for antigen retrieval using citric acid. Immunohistochemistry was performed according to standard methods using a DAKO autostainer (DAKO Corp., Carpinteria, CA) and the following antibodies: osteopontin (OPN), working dilution 1:100 (Mouse monoclonal, Developmental Studies Hybridoma Bank, The University of Iowa, Iowa City, IA); ED-1, working dilution 1:500 (Chemicon Inc., Temlecula, CA); and CD-3, working dilution 1:300 (DAKO). Positive immunoreactivity was detected using a horseradish peroxidase-conjugated secondary antibody and the substrate diaminobenzidine (DAKO). Isotype-matched IgGs at similar concentrations were used in place of the primary antibodies for negative controls. Tissues known to express these targets were used as positive controls. Immunoreactivity in the cardiac sections was scored on a scale from 0 (absent) to 4 (marked).
Biochemical Assays. TNF-α, tissue necrosis factor receptors 1 and 2 (TNFR1 and TNFR2), and interleukin-6 (IL-6) were quantitated according to standard procedures. Serum TNF-α was analyzed by ELISA utilizing an Ultra Sensitive rat TNF-α kit (Biosource International, Camarillo, CA). Plasma TNFR1 and TNFR2 levels were determined using Quantikine M mouse sTNFR1 and sTNFR2 Immunoassay kits (R & D Systems, Minneapolis, MN). Plasma IL-6 was determined using a rat IL-6 ELISA (Biosource, Camarillo, CA). Urinary proteinuria was determined using the Bio-Rad protein dye reagent (Bio-Rad Laboratories, Hercules, CA). The assay was modified to a 96-well plate format according to the manufacturer's instructions. Matrix metalloproteinase-2 and -9 (MMP-2 and MMP-9) activity was examined by zymography in heart extracts. Briefly, LV tissue samples were homogenized in 25 mL ice-cold extraction buffer containing 1% Triton X-100, 25 mM HEPES, 0.15 M NaCl, 2 mM EDTA, and a complete protease inhibitor cocktail (Roche, Indianapolis, IN) The homogenates were centrifuged (4°C, 8000×g, 20 min), protein concentrations were assessed with the use of a bicinchoninic acid assay (Pierce, Rockford, IL), and equivalent amounts were separated by SDS-PAGE. After electrophoresis, gels were washed and allowed to renature for 1 hour. Gels were incubated at 37°C for [16] [17] [18] RNA isolation. RNA was extracted from frozen heart tissue using the Totally RNA Isolation Kit (Ambion, Inc., Austin, TX) as previously described (19) . Tissues were crushed, homogenized, and denatured according to manufacturer's instructions. RNA was further purified by DNase digestion to remove genomic DNA and LiCl precipitation to remove carbohydrates. Purified RNA was precipitated with 7.5 M LiCl/50 mM EDTA, and incubated overnight at -80°C. All samples were diluted and analyzed spectrophotometrically for concentration and purity and stored at -80°C.
Taqman Quantitative RT-PCR. All primers and probes were designed using Primer Express software supplied with the 7700 Sequence Detection System based on known rat sequences and synthesized by Applied Biosystems (Foster City, CA) as previously described Table 1 . All oligonucleotides are written 5' -3'. Primers were unlabeled and all probes were labeled at the 5' end with 6-carboxyfluorescein (6FAM) reporter dye and at the 3' end with 6-carboxy-N,N,N',N'-tetramethylrhodamine (TAMRA) quencher dye. Expression levels in SHHF animals were compared to message levels in control, 4-month-old Lewis rats.
Statistical Analysis. For all parameters excluding histology and gene expression data, there were four distinct groups, each group comprised of SHHF rats at different ages: 4, 9, 15, and 18 months of age. For histological parameters groups were 5, 9, 16 and 18 months of age.
The gene expression analysis was performed on SHHF animals aged 4, 9, 12 and 15 months of age with the inclusion of a 4 month-old Lewis rat control animal. Data were analyzed using one-way analysis of variance (ANOVA). Taqman statistics were performed on the rank transforms of the raw data (nonparametric analysis) to account for any inequality of variance. The age group means for the gene expression variables were compared to Lewis rat control group using the Least Significant Differences (LSD) means comparison procedure. The age group means for the physiological, echocardiographic and biochemical variables were compared to all other group means using two-tailed Tukey's studentized range test (HSD). Data means which were found to be significantly different from other means with Tukey's HSD were assigned different letters.
Data were analyzed using PROC GLM in the SAS statistical software package (SAS PC, version 6.12, SAS Institute, Cary, NC). All data are reported as mean ± standard error mean (SEM).
Results
Physiological Analysis. The comparison of body weight (BW), systolic blood pressure (SBP) and proteinuria in the SHHF model over time is shown in Table 2 . SHHF animals were hypertensive compared to normal Sprague Dawley rats (SBP; 110-130 mmHg, (2)) as early as 4 months of age and systolic blood pressure continued to rise as heart failure developed. Animals entering into mid-and late-stage heart failure (~16-18 months of age) demonstrated decreases in SBP concurrent with a large increase in urinary protein levels.
Echocardiographic Analysis. A comprehensive temporal echocardiographic evaluation
of SHHF pathophysiology demonstrated progressive, marked changes in cardiac structure and function (Table 3 ). All echocardiographic parameters changed with age and several notable changes are described in detail. At 4 and 9 months wall thickness was significantly increased compared to 15 and 18 month SHHF animals (RWT 45.4 ± 1.5, 4 mo and 45.7 ± 1.3, 9 mo vs. 37.5 ± 1.6, 15 mo and 29.6 ± 1.1, 18 mo), whereas older animals exhibited significant increases in left ventricular end diastolic and end systolic volume and area compared to earlier timepoints, accompanied by diminishing RWT. Beginning at 15 months of age significant loss of cardiac function was also apparent. EF and FS were decreased from 45.3 ± 1.4 at 15 months to 29.1 ± 2.5 at 18 months and 28.8 ± 1.0 at 15 months to 16.1 ± 0.9 at 18 months, respectively.
Moreover, doppler echocardiographic analysis revealed progressive diastolic dysfunction characterized by augmented early E-vel and diminished A-vel with age, which is indicative of abnormal diastolic filling. Furthermore, Decel T was attenuated and paralleled by shorter isovolumetric relaxation times (IR). Consistent with age-dependent changes in blood pressure and body weight, temporal echocardiographic analysis indicated progressive cardiac dysfunction concomitant with deleterious LV remodeling as SHHF animals transitioned from a compensated, hypertrophic state to decompensated heart failure.
Histopathology and Immunohistochemistry. Myocardial lesions and inflammatory
infiltrates were assessed in 5-, 9-, 16-and 18-month-old SHHF rats. Lesions were absent in 5-month-old SHHF rats. In older SHHF rats, there was a progressive increase in the incidence and/ or severity of myocardial fibrosis and degeneration (Table 4) .
Interstitial fibrosis was present in all rats by 9 months of age and increased in severity from minimal (single or multiple small foci of fibrosis) at 9 months of age to minimal to mild at 16 months of age. Myocardial interstitial fibrosis was limited to the left ventricle and ventricular septum in 9-and 16-month-old rats. There was a striking increase in the amount of histologically evident interstitial fibrosis between 16 and 18 months. At 18 months, the fibrosis was moderate and was characterized by diffuse fibrosis of the myocardium in the zone extending from the lumenal surface to approximately the midmyocardium of the left ventricular wall.
Fibrosis was less evident in the interventricular septum and minimal fibrosis was detected in the right ventricular wall. Interstitial fibrosis was quantified and summarized as collagen volume fraction. The collagen volume fraction (CVF) increased progressively as the rats aged ( Figure   1A ). Perivascular fibrosis surrounding intramyocardial coronary arteries and arterioles was generally concomitant with the interstitial fibrosis ( Figure 1B -1E ). Negligible evidence of perivascular fibrosis was evident at 5 months of age. Perivascular fibrosis was minimal at 9 months with severity increasing to mild at 18 months ( Table 4 ).
As listed in Table 4 , focal myocyte degeneration was observed in areas of most intense fibrosis and scattered, single, necrotic myocytes were present in the fibrotic areas in some of the hearts in 9-and 16-month-old rats and in all of the hearts of 18-month-old rats. Myocardial inflammation was absent at 5 months and consisted of minimal infiltrates of monocytes and macrophages in foci of myocyte necrosis and loss in 9-, 16-, and 18-month-old rats. Myocardial hypertrophy, which was most prominent in the inner half of the left ventricular wall in 9-and 16-month old rats, was less evident in the fibrotic hearts of 18-month-old rats ( Table 4 ).
The inflammatory cell infiltrate was further characterized using immunohistochemical analysis. Cells adhering to the endothelium and infiltrating into the perivascular and interstitial space in the areas of myocyte loss reacted positively with monocyte/macrophage antibody, ED-1. (Fig. 3C) .
Biochemical Analysis. The mechanisms underlying the developing SHHF pathophysiology were investigated by monitoring circulating markers of inflammation and remodeling in animals at 4, 9, 16, and 18 months of age (Table 5 ). Circulating levels of TNFR1, TNFR2, TNF-α, and IL-6 significantly increased in 18-month-old animals compared to earlier timepoints. Similar to the human disease state, these inflammatory markers are significantly elevated in more advanced HF. Finally, MMP zymographic activity analysis demonstrated peak gelatinase activity at 18 months of age (Figure 4) .
Transcriptional Profiling Analysis.
To further characterize the molecular mechanisms underlying the progression from hypertension to heart failure in 4-15 month old rats, we evaluated the expression of multiple genes in heart tissue using quantitative RT-PCR. Consistent with histological evidence of infiltrating inflammatory cells, several pro-inflammatory markers were modulated over time with disease progression in the SHHF rat (Table 6 ). OPN gene expression was markedly elevated by 4 months of age (~11-fold), and further increased up to ~15-fold by 15 months of age compared to control. COX-2, IL-1β, IL-6, and ICAM-1 exhibited a different expression pattern where expression was highest at 9 months followed by a downregulation of expression at 12 and 15 months of age. By 9 months, COX-2 mRNA expression increased (~5-fold), IL-1β (~4-fold), IL-6 (~14-fold) and ICAM -1(~1.4-fold). VCAM-1 expression was modestly elevated (~1.3 fold) at 4 and 9 months of age followed by normalization of expression by 12 months of age. In contrast, gene expression of iNOS and TNF-α was somewhat attenuated over time as the pathology persisted with the lowest expression level exhibited at 15 months of age.
The molecular mechanisms of advancing structural changes in the heart were also evaluated (Table 6 ). Gene expression analysis of stress/structural genes revealed a marked upregulation of ANP which was significant at 9 months (~22 fold) and remained high through 12 (~19 fold) and 15 month (~15 fold) of age compared to control rats. Also consistent with the hypertrophic phenotype of younger SHHF rats, both BNP and ET-1 genes were exhibiting elevated expression at 4 months of age (~5 fold and ~1.9 fold, respectively) and remained high through 15 months of age compared to control animals. Moreover, expression of the fetal myosin isoform MHC-β was increased ~4 fold by 4 months and remained high until 15 months of age where expression was slightly decreased. Expression of the adult isoform, MHC-α, was correlatively down regulated with age similar to ACE message levels. Increased expression of the naturetic peptides, ET-1, and the reversal of the MHC α/β isoform expression is consistent with continued increasing blood pressure and the presence of compensated hypertrophy in aging SHHF rats. Finally, a modest, albeit significant, progressive increase in the proinflammatory cytokine, TGF-β, parallels the age-dependent increase in interstitial collagen.
The molecular mechanisms of the extensive myocardial remodeling evidenced by echocardiographic analysis were evaluated by monitoring quantitative changes in the extracellular matrix gene expression (Table 6) . COL-I, COL-III and FN expression remained largely unchanged over time. MMP-2, MMP-8, and MT1-MMP displayed a biphasic temporal pattern where expression was elevated early and late in the timecourse compared to control rats.
In contrast, MMP-3 message levels were low at 4 months of age and remained diminished over the time course of the study. TIMP expression, however, displayed a slightly different expression pattern. TIMP-1 and -2 message levels were upregulated by 4 months and remained elevated, whereas TIMP-4 expression was attenuated over time. Thus, the integrated network of molecular mechanisms underlying the hallmark structural and functional alterations accompanying SHHF pathophysiology likely include inflammation, a cellular hypertrophic response, and extracellular matrix remodeling.
Discussion
The objective of the current study is to provide a foundation for further studies with standard therapies. The applicability of studies in untreated animals to clinical findings is limited by the fact that nearly all treated heart failure patients are receiving multiple pharmaceutical interventions. However, it is paramount to the understanding of the impact and mechanisms of action of therapeutic agents that the characteristics of HF be defined. By contributing a comprehensive echocardiographic and molecular evaluation of HF pathophysiology to the knowledge base, it is anticipated that a greater appreciation of the impact of treatment on the drivers of HF will be achieved. Thus, a novel comprehensive evaluation of the structural, functional, and molecular progression of HF was conducted in the lean male SHHF rat model. In the compensated state, animals were hypertensive as early as 4 months of age with accompanying myocardial hypertrophy clearly evidenced by 9 months of age as demonstrated by increased expression of molecular hypertrophic/stress markers, increased relative wall thickness, and preserved function. As described previously, animals begin to transition to a decompensated state around 15 months of age (21) and many hallmark features of late-stage HF such as myocardial inflammation, increased chamber size, and diminishing EF were evidenced. Circulating cytokines and their receptors are now being established as markers of human HF severity and patient survival (11, 28, 29) . Consistent with human CHF, circulating TNF-α was found to be progressively elevated in SHHF rats with age and disease advancement. In contrast, myocardial TNF-α expression is modestly decreased with age. The observed dissociation between circulating TNF-α levels and myocardial expression is not surprising as even an 11-fold overexpression of myocardial TNF-α does not result in elevated circulating TNF-α in transgenic mouse models (4) . In addition to TNF-α, both IL-6 and the soluble forms of TNF-α receptors (R1 and R2) were also found to be elevated in NYHA class III and IV HF patients and SHHF rats with late-stage heart failure (11, 28) . Indeed, IL-6 has been demonstrated as a prognosticator of mortality (29) and elevated IL-6 levels have been positively correlated to increases in end diastolic and systolic volumes (28).
In addition to IL-6, the expression of levels of other inflammatory markers including IL-1β, COX-2, and ICAM-1 were all highest at 9 months of age prior to decompensation. These molecules are established mediators of the inflammatory response. Thus, decompensation in the SHHF rat may be preceded by an inflammatory burst that initiates the recruitment of cellular infiltrates and activation of signaling pathways that may initially be reparative, but eventually become maladaptive with long exposure.
Rapidly emerging as a key contributor to myocardial remodeling and inflammation, the cytokine and potent macrophage chemoattractant, OPN, is expressed by a number of cell types including cardiomyoctyes and participates in cell adhesion, chemotaxis, and cellular signaling (9, 10) . Although OPN expression has been shown to be elevated in spontaneously hypertensive rats and cardiomyopathic hamsters with CHF (32, 39), the current study is the first to describe the role of OPN in the SHHF rat. Myocardial remodeling resulting from hypertension or infarction is positively correlated with elevated cardiac expression of OPN suggesting a function for this adhesion molecule in myocardial structural alterations that accompany external stress (12, 37) . Thus, in this model it is likely that this adhesion molecule serves a role in both monocyte/macrophage recruitment and adherence and myocardial remodeling that typifies HF progression.
In addition to inflammation, components and modulators of the extracellular matrix serve key functions in compensatory and maladaptive LV remodeling that accompanies human CHF development (38). Structural changes were also evident in aging SHHF rats. Although collagen and FN message remained unchanged from 4 to 18 months of age, myocardial fibrosis was progressively elevated. These findings parallel previous studies by Li et al. which demonstrated an increase in collagen volume fraction in SHHF animals in the absence of increased COL-I or COL-III expression. The apparent disparity between message and protein levels for these structural molecules is most likely explained by post-translational processing (15) . As the principle regulators of the extracellular matrix, MMPs and TIMPs have been shown to be selectively modulated with CHF progression. Indeed, both MMP and TIMP mRNA levels have been shown to be upregulated in patients and obese SHHF male rats and inhibition of MMPs attenuated LV remodeling in SHHF and post myocardial infarction rat models of HF (17, 26, 27 ). In the present study, lean male SHHF animals also demonstrated augmented levels of MMP and TIMP expression with the exception of MMP-3. These data are consistent with published studies in obese, male SHHF rats where MMP-3 message was not elevated in the SHHF animals at age 9 and 13 months (17) . Collectively, these data suggest that LV remodeling over the course of CHF progression is a deliberate and highly orchestrated molecular process integrating a selective inflammatory response with extracellular matrix adaptations.
SHHF rats progress from a spontaneously hypertensive, compensated phenotype to overt, late-stage CHF. During the course of CHF development, a multitude of maladaptive molecular and cellular systems are initiated culminating with the advancement to the end-stage disease.
Although experimental models are recognized approximations of human pathophysiology, the SHHF model shares many common features with the human disease state. In this regard, the SHHF rat offers a unique opportunity to dissect the complex molecular and cellular, and physiological network of compensatory and decompensatory drivers of heart failure. control. † All expression levels were normalized to the housekeeping gene, cyclophilin, which was set at 1. ‡ SHHF rat expression levels are compared to message levels in control animals, 4-month old Lewis rats. OPN, osteopontin; COX-2, cyclooxygenase; IL-1 β, interleukin-1 beta; IL-6, interleukin-6; ICAM-1, intercellular adhesion molecule; VCAM-1, vascular cell adhesion molecule; TNF-α, tumor necrosis factor alpha; iNOS, inducible nitric oide synthase; ANP, atrial natriuretic peptide; BNP, brain natriuretic peptide; ET-1, endothelin; MHC-β, myosin heavy chain beta; MHC-α, myosin heavy chain alpha; ACE, angiotensin converting enzyme; TGF-β, transforming growth factor; COL- 
